Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Britain Courts Anthropic Amid US Defense Department Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SAN DIEGO, July 26, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2017 financial results after the market closes on Thursday, August 3, 2017 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 58660651. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on August 3, 2017 to 7:30 p.m. ET on August 10, 2017. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 58660651.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact: Vital Therapies, Inc. Al Kildani Vice President, Investor Relations and Business Development 858-673-6840 [email protected]
